Abstracts tagged "Administrative Data"

Abstract Number: 1583 • ACR Convergence 2025
Epidemiology, Outcome and Expenditures of Hospitalized Patients with Systemic Sclerosis: National Inpatient Sample 2021
Patompong Ungprasert¹ and Paul Kroner², ¹Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH, ²Riverside Health System, Newport News, VA
Background/Purpose: The inpatient epidemiology, morbidity, mortality, and healthcare expenditures of patients with systemic sclerosis (SSc) are not well-characterized. This study aims to utilize a nationwide…
Abstract Number: 0145 • ACR Convergence 2025
Population Assessment of Cancer Incidence among Patients with Idiopathic Inflammatory Myopathies in North Carolina
Astia Allenzara¹, Ben Albright², Xi Zhou², Amanda Nelson³, Laura Green⁴, Katherine Reeder-Hayes⁴, Jennifer Lund⁴, Caroline Thompson⁴ and Chris Baggett⁴, ¹UNC, Chapel Hill, NC, ²University of North Carolina, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴University of North Carolina, Chapel Hill
Background/Purpose: Cancer is highly prevalent and a leading cause of death for patients with Idiopathic Inflammatory Myopathies (IIM). Evaluating cancer type and stage at diagnosis…
Abstract Number: 2642 • ACR Convergence 2025
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism: A Population-Based Cohort Study
Mohammad Movahedi¹, Angela Cesta¹, Sibel Aydin², Pooneh Akhavan³, Tetyana Kendzerska⁴, Claire Bombardier¹ and Bindee Kuriya⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ³self-employed, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Mississuaga, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). Inflammation is a driver of…
Abstract Number: 1497 • ACR Convergence 2025
Acute Care Utilization in Patients with Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus
Megan Barber¹, Fengjuan Yang², Leslie Skeith², Danielle Southern³ and Ann Clarke¹, ¹Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²University of Calgary, Calgary, AB, Canada, ³University of Calgary, Calgary, Canada
Background/Purpose: Little is known about acute care utilization in patients with APS and/or SLE. This study focuses on hospitalizations, intensive care unit (ICU) admissions and…
Abstract Number: 2627 • ACR Convergence 2025
Risk of Adverse Pregnancy Outcomes in Individuals with Rheumatic Diseases Using Prenatal Antirheumatic Drugs: a Population-Based Cohort Study
Shenthuraan Tharmarajah¹, Dharini Mahendira², Swaleh Hussain¹, Howard Berger³, Sara Guilcher⁴, Lisa McCarthy⁴ and Mina Tadrous¹, ¹University of Toronto, Toronto, ON, Canada, ²St Michael's Hospital, Toronto, Canada, ³St. Michael's Hospital, Toronto, Canada, ⁴University of Toronto, Toronto, Canada
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) are the primary class of drug therapies generally used to treat rheumatic diseases, such as rheumatoid arthritis (RA), systemic lupus…
Abstract Number: 1434 • ACR Convergence 2025
Safety of Prescription NSAIDs in Adults with IBD: Data from a Large Administrative Claims Cohort
Adam Mayer¹, Rui Xiao², Meenakshi Bewtra³, Michael George⁴ and Pamela Weiss⁵, ¹University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The potential that nonsteroidal anti-inflammatory drugs (NSAIDs) may precipitate flares of inflammatory bowel disease (IBD) has limited their use in managing joint pain in…
Abstract Number: 2295 • ACR Convergence 2025
Autoantibody Profiles and Their Association with Organ Involvement in Primary Sjögren’s Syndrome: Insights from ESSDAI
Deepak Rath¹, Sholen Acharya² and Dr Alakendu Ghosh³, ¹John H Stroger Hospital Jr of Cook County, Chicago, Illinois, USA, ⁶⁰⁶¹², Chicago, IL, ²Department of Reproductive Medicine and Surgery, Government Medical College Thiruvananthapuram, Kerala, India, ⁶⁹⁵⁰⁰⁴, Chicago, IL, ³Self employed, Kolkata, West Bengal, India
Background/Purpose: To evaluate the clinical manifestations, systemic disease activity, and serological profile of patients of Primary Sjögren’s syndrome, and to assess associations between specific autoantibodies…
Abstract Number: 1100 • ACR Convergence 2025
Associations Between Pre-Existing Autoimmunity and CAR T Cell Therapy Toxicity for Cancer Treatment: A Nationwide Retrospective Cohort Study
Gregory Challener¹, Chen Wang², David Gritsch², Ilana Usiskin³, Zandra E. Walton¹, Minna Kohler⁴, Hyon K. Choi⁵ and Jeffrey Sparks⁶, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ²Harvard T.H. Chan School of Public Health, Boston, ³Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Chimeric antigen receptor (CAR) T cell therapy is being investigated to treat individuals with autoimmune diseases. Data regarding the safety of CAR T cell…
Abstract Number: 2287 • ACR Convergence 2025
Interpretable Ensemble Machine Learning Explaining Nonadherence and the Risk of Nonpersistence of Targeted Disease-Modifying Antirheumatic Agents in Older Adults with Rheumatoid Arthritis
yinan huang¹ and Sandeep Agarwal², ¹Department of Pharmacy Administration, University of Mississippi, Oxford, MS, US, MS, ²Baylor College of Medicine, Houston
Background/Purpose: Interpretable machine learning (ML) method can identify factors associated with biological or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) nonadherence and nonpersistence for rheumatoid…
Abstract Number: 1084 • ACR Convergence 2025
Access to rheumatology care in patients with new diagnosis of polymyalgia rheumatica: analysis from a national inception cohort
Sebastian E Sattui¹, Orysya Soroka², Manuel Carpio Tumba³, Emily Holladay⁴, Fenglong Xie⁵, Sarah Mackie⁶, Jeffrey Curtis⁷, Robyn Domsic³ and Iris Navarro-Millan⁸, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Weill Cornell Medicine, New York, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Alabama at Birmingham, Edmond, OK, ⁵The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Leeds, Leeds, United Kingdom, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY
Background/Purpose: Patients with polymyalgia rheumatica (PMR) are commonly diagnosed and cared for by non-rheumatology providers (i.e., primary care). Lack of access to specialty care can…
Abstract Number: 2266 • ACR Convergence 2025
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of All-Cause Mortality and All-Cause Cancer: A Population-Based Cohort Study
Mohammad Movahedi¹, Angela Cesta¹, Sibel Aydin², Pooneh Akhavan³, Tetyana Kendzerska⁴, Claire Bombardier¹ and Bindee Kuriya⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ³self-employed, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Mississuaga, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Observational studies on RA therapeutic classes have shown conflicting results on their impact on mortality and cancer. When analyzing long-term outcomes, it is essential…
Abstract Number: 1054 • ACR Convergence 2025
Comedication Patterns of Romosozumab Early Adopters Among Medicare Enrollees: An Unsupervised Clustering Approach
Ye Liu¹, Hongke Wu¹, Tarun Arora² and Jeffrey Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²FASTER, Birmingham, AL, ³Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Polypharmacy is a major concern in osteoporosis (OP) management, especially in older adults. Romosozumab (romo), approved in April 2019, is a parenteral OP medicine…
Abstract Number: 2202 • ACR Convergence 2025
Epidemiologic Evaluation of Postpartum Mental Health for Women Living with Systemic Lupus Erythematosus: A Population-Based Cohort Study Among Medicaid Enrollees
Alyssa Howren¹, Amadeia Rector², Sadaf Sediqi³ and Julia F Simard⁴, ¹Stanford University, Menlo Park, CA, ²Stanford University, San Francisco, CA, ³Stanford University, Palo Alto, CA, ⁴Stanford Medicine, Stanford, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune rheumatic disease, predominately affecting women during their reproductive years. Despite widespread evidence that individuals with SLE…
Abstract Number: 1017 • ACR Convergence 2025
Effectiveness of Recombinant Zoster Vaccine in Reducing Herpes Zoster Incidence and All-Cause Mortality Among Rheumatoid Arthritis Patients: A Retrospective Cohort Study of 21,046 Individuals from TriNetX U.S. Collaborative Network
James Wei¹, Shiow-Ing Wang² and Ying-Li Lin², ¹Chung Shan Medical University Hospital, Taichung, Taichung, Taiwan (Republic of China), ²Chung Shan Medical University Hospital; China Medical University, Taichung, Taiwan (Republic of China)
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing herpes zoster (HZ). This study aimed to assess the effectiveness of recombinant zoster…
Abstract Number: 2051 • ACR Convergence 2025
Clinical Burden of Illness Among Patients with Immunoglobulin-G4-Related Disease in the United States
Sushmitha Inguva¹, Emma Culver², Pallavi Rane¹, Laura Moore-Schiltz³, melissa rosen⁴, Kristina Patterson⁴, Donna McMorrow³, Zulkarnain Pulungan⁵, Yasmin Hernandez-Barco⁶ and John Stone⁷, ¹Amgen Inc., Thousand Oaks, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Inovalon, Bowie, MD, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Inovalon, Bowie, ⁶Massachusetts General Hospital; Harvard Medical School, Boston, MA, ⁷Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: Immunoglobulin G4-related disease (IgG4-RD) is a multi-organ, immune-mediated condition. Timely treatment is critical, as disease flares often result in increased inflammation and organ damage.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].